HEPA Hepion Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HEPA

Price (delayed)

$1.46

Market cap

$7.99M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$12.32

Enterprise value

-$6.59M

The Company's lead drug candidate, CRV431, is a potent inhibitor of cyclophilins, which are involved in many disease processes. CRV431 is currently in clinical-phase development for the treatment of NASH, ...

Highlights
HEPA's debt is down by 13% since the previous quarter
Hepion Pharmaceuticals's equity has plunged by 85% YoY and by 55% from the previous quarter
Hepion Pharmaceuticals's quick ratio has plunged by 57% YoY and by 7% from the previous quarter
Sector: Healthcare
Industry: Biotechnology
Website: http://hepionpharma.com
Peers: OMER OMGA

Key stats

What are the main financial stats of HEPA
Market
Shares outstanding
5.47M
Market cap
$7.99M
Enterprise value
-$6.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
0.87
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$49.33M
EBITDA
-$49.26M
Free cash flow
-$40.9M
Per share
EPS
-$12.32
Free cash flow per share
-$10.3
Book value per share
$1.68
Revenue per share
$0
TBVPS
$4.56
Balance sheet
Total assets
$18.09M
Total liabilities
$10.81M
Debt
$209,020
Equity
$7.28M
Working capital
$12.2M
Liquidity
Debt to equity
0.03
Current ratio
3.31
Quick ratio
2.8
Net debt/EBITDA
0.3
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-151.6%
Return on equity
-225%
Return on invested capital
N/A
Return on capital employed
-385.2%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HEPA stock price

How has the Hepion Pharmaceuticals stock price performed over time
Intraday
-2.67%
1 week
6.57%
1 month
-41.83%
1 year
-99.44%
YTD
-54.94%
QTD
-41.37%

Financial performance

How have Hepion Pharmaceuticals's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$48.45M
Net income
-$48.93M
Gross margin
N/A
Net margin
N/A
HEPA's net income is down by 16% year-on-year and by 10% since the previous quarter
The operating income has contracted by 7% YoY

Growth

What is Hepion Pharmaceuticals's growth rate over time

Valuation

What is Hepion Pharmaceuticals stock price valuation
P/E
N/A
P/B
0.87
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HEPA's EPS is down by 3.5% YoY
Hepion Pharmaceuticals's equity has plunged by 85% YoY and by 55% from the previous quarter
The stock's price to book (P/B) is 46% less than its last 4 quarters average of 1.6 and 21% less than its 5-year quarterly average of 1.1

Efficiency

How efficient is Hepion Pharmaceuticals business performance
The return on assets has dropped by 159% year-on-year and by 36% since the previous quarter
Hepion Pharmaceuticals's ROE has plunged by 52% from the previous quarter

Dividends

What is HEPA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HEPA.

Financial health

How did Hepion Pharmaceuticals financials performed over time
The total assets is 67% more than the total liabilities
The total assets has plunged by 70% YoY and by 28% from the previous quarter
Hepion Pharmaceuticals's quick ratio has plunged by 57% YoY and by 7% from the previous quarter
HEPA's debt is 97% smaller than its equity
Hepion Pharmaceuticals's debt to equity has soared by 200% from the previous quarter
Hepion Pharmaceuticals's equity has plunged by 85% YoY and by 55% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.